ЭКСТРАКОРПОРАЛЬНОЕ ОЧИЩЕНИЕ КРОВИ В ИНТЕНСИВНОЙ ТЕРАПИИ ОСТРОЙ ПЕЧЕНОЧНОЙ НЕДОСТАТОЧНОСТИ

  • Р. Э. Якубцевич (R. E. Yakubtsevich) Гродненский государственный медицинский университет https://orcid.org/0000-0002-8699-8216
Ключевые слова: острая печеночная недостаточность, гемокарбоперфузия, плазмаферез, экстракорпоральная поддержка печени, живые культуры гепатоцитов

Аннотация

Интенсивная терапия острой печеночной недостаточности включает применение гепатопротекто- ров, интракорпоральной детоксикации, коррекции коагулопатии и энцефалопатии, а в случае фульминантной формы – трансплантации печени. Использование методов экстракорпорального очищения крови имеет место в большинстве случаев лечения данной патологии. Однако выбор того или иного метода, а также сроки их применения остаются предметом дискуссий. В обзоре литературы представлен анализ 46 литературных источников с целью изучения современных подходов к применению методов экстракорпорального очищения крови при острой печеночной недостаточности.

Литература


1. Gawande A, Gupta GK, Gupta A, Wanjari SJ, Goel V, Rathore V, Bhardwaj H, Nijhawan S. Acute-on-hronic liver failure: etiology of chronic and acute precipitating factors and their effect on mortality. J. Clin. Exp. Hepatol. 2019;9(6):699-703. doi: 10.1016/j.jceh.2019.04.050.


2. Montrief T, Koyfman A, Long B. Acute liver failure: a review for emergency physicians. Am. J. Emerg. Med. 2019;37(2):329-337. doi: 10.1016/j.ajem.2018.10.032.


3. Blackmore L, Bernal W. Acute liver failure. Clin. Med. 2015;15(5):468-472. doi: 10.7861/clinmedicine.15-5-468.


4. Polushin JuS. Anesteziologija i reanimatologija. Moscow: Specialnoe izdatelstvo medicinskih knig; 2016. 784 p. (Russian).


5. Chayanupatkul M, Schiano TD. Acute liver failure secondary to drug-induced liver injury. Clin. Liver. Dis. 2020;24(1):75-87. doi: 10.1016/j.cld.2019.09.005.


6. Szabo G. Pathogenesis of acute on chronic liver failure in patients with infection. Clin. Liver Dis. 2019;14(3):103-106. doi: 10.1002/cld.826.


7. Karvellas CJ, Tillman H, Leung AA, Lee WM, Schilsky ML, Hameed B, Stravitz RT, McGuire BM, Fix OK. Acute liver injury and acute liver failure from mushroom poisoning in North America. Liver Int. 2016;36(7):1043-1050. doi: 10.1111/liv.13080.


8. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin. Proc. 2014;89(1):95-106. doi: 10.1016/j. mayocp.2013.09.016.


9. Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Young WL. Miller’s Anesthesia. 8th ed. Philadelphia: Elsevier Saunders; 2015. 3576 p.


10. Lee WM. Etiologies of acute liver failure. Semin Liver Dis. 2008;28(2):142-152. doi: 10.1055/s-2008-1073114.


11. Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: a perspective from Japan. J. Gastroenterol. Hepatol. 2011;26(1):65-71. doi: 10.1111/j.1440-1746.2010.06574.x.


12. Lukashik SP, Karpov IА. Ostraja respiratornaja nedostatochnocht u vzroslyh [Acute liver failure in adults]. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija [Clinical Microbiology and Antimicrobial Chemotherapy]. 2019;21(1):46-55. doi.org/10.20514/2226-6704-2017-7-3-171-180. (Russian).


13. Ash SR. Extracorporeal blood detoxification by sorbents in treatment of hepatic encephalopathy. Adv. Ren. Replace. Ther. 2002;9(1):3-18. https://doi.org/10.1053/jarr.2002.30474.


14. Lee K, Mun CH, Min BG. Development of a multifunctional detoxifying unit for liver failure patients. Blood Purif. 2012;34(3-4):225-230. doi: 10.1159/000341552.


15. Irmatov S, Sadykov R, Ibadov R, Kim O. Jeksperimentalnye issledovanija sravnitelnoj jeffektivnosti gemo-, plazma- i ascitosobcii pri pechenochnoj nedostatochnosti [Experimental study of comparative effectiveness of hemo-, plasma- and ascites sorption in liver failure]. Universum: Medicina i farmakologija. 2017;2(36):11-21. (Russian).


16. Ash SR, Sullivan TA, Carr DJ. Sorbent suspensions vs. sorbent columns for extracorporeal detoxification in hepatic failure. Ther. Apher. Dial. 2006;10(2):145-153. doi: 10.1111/j.1744-9987.2006.00356.x.


17. Chang TM, Lister C. Analysis of possible toxins in hepatic coma including the removal of mercaptan by albumin-collodion charcoal. Int. J. Artif. Organs. 1980;3(2):108-112.


18. Kieslichova E, Frankova S, Protus M, Merta D, Uchytilova E, Fronek J, Sperl J. Acute liver failure due to amanita phalloides poisoning: therapeutic approach and outcome. Transplant. Proc. 2018;50(1):192-197. doi: 10.1016/j. transproceed.2017.11.032.


19. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue. J. Clin. Apher. 2016;31(3):149–162. doi: 10.1002/jca.21470.


20. Stahl K, Hadem J, Schneider A, Manns MP, Wiesner O, Schmidt BMW, Hoeper MM, Busch M, David S. Therapeutic plasma exchange in acute liver failure. J. Clin. Apher. 2019;34(5):589-597. doi: 10.1002/jca.21737.


21. Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, Triantafyllou E, Bernal W, Auzinger G, Shawcross D, Eefsen M, Bjerring PN, Clemmesen JO, Hockerstedt K, Frederiksen HJ, Hansen BA, Antoniades CG, Wendon J. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J. Hepatol. 2016;64(1):69-78. doi: 10.1016/j. jhep.2015.08.018.


22. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the six special issue. J. Clin. Apher. 2013;28(3):145-284. doi: 10.1002/jca.21276.


23. Pratasevich PP, Yakubtsevich RE, Savastyanik SA, Yurkevich LA. Plazmaferez kak faktor riska razvitija tromboticheskih oslozhnenij [Plasmapheresis as a factor of the risk of thrombothic complications]. Medicinskie Novosti [Medical News]. 2018;10:43-44. (Russian).


24. Cheng YL, Chang CH, Chen WT, Tsai MH, Lee WC, Tu KH, Tian YC, Chen YC, Hung CC, Fang JT, Yang CW, Chang MY. Prognostic factors and treatment effect of standard-volume plasma exchange for acute and acuteon-chronic liver failure: a single-center retrospective study. Transfus. Apher. Sci. 2018;57(4):537-543. doi: 10.1016/j. transci.2018.05.030.


25. Li M, Wang Z, Wang Y, Du C, Li S, Shi Z, Lu B. Part of plasmapheresis with plasma filtration adsorption combined with continuous hemodiafiltration in the treatment of severe acute liver failure. Exp. Ther. Med. 2016;12(4):2582-2584. doi: 10.3892/etm.2016.3633.


26. Riveiro-Barciela M, Munoz-Couselo E, Fernandez-Sojo J, Diaz-Mejia N, Parra-Lopez R, Buti M. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies? J. Hepatol. 2019;70(3):564-566. doi: 10.1016/j. jhep.2018.10.020.


27. Baтares R, Ibanez-Samaniego L, Torner JM, Pavesi M, Olmedo C, Catalina MV, Albillos A, Larsen FS, Nevens F, Hassanein T, Schmidt H, Heeman U, Jalan R, Moreau R, Arroyo V. Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. Ther. Adv. Gastroenter. 2019;12. https://doi. org/10.1177/1756284819879565.


28. Chawla LS, Georgescu F, Abell B, Seneff MG, Kimmel PL. Modification of continuous veno-venous hemodiafiltration with single-pass albumin dialysate allows for removal of serum bilirubin. Am. J. Kid. Dis. 2005;45(3):e51-56. doi: 10.1053/j.ajkd.2004.11.023.


29. Wittebole X, Hantson P. Use of the molecular adsorbent recirculating system (MARS) for the management of acute poisoning with or without liver failure. Clin. Toxicol. 2011;49(9):782-793. doi: 10.3109/15563650.2011.624102.


30. Lexmond WS, Van Dael CM, Scheenstra R, Goorhuis JF, Sieders E, Verkade HJ, Van Rheenen PF, Kömhoff M. Experience with molecular adsorbent recirculating system treatment in 20 children listed for high-urgency liver transplantation. Liver Transpl. 2015;21(3):369-380. doi: 10.1002/lt.24037.


31. Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner C, Stauber RE. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute on chronic liver failure. Crit. Care. 2006;10(6):R169. doi: 10.1186/cc5119.


32. Rifai K. Fractionated plasma separation and adsorption: current practice and future options. Liver Int. 2011;31(Suppl 3):13-15. doi: 10.1111/j.1478-3231.2011.02595.x.


33. Stankiewicz R, Lewandowski Z, Kotulski M, Patkowski W, Krawczyk M. Effectiveness of fractionated plasma separation and absorption as a treatment for amanita phalloides poisoning. Ann. Transplant. 2016;21:428-432. doi: 10.12659/aot.897351.


34. Komardina E, Yaroustovsky M, Abramyan M, Plyushch M. Prometheus therapy for the treatment of acute liver failure in patients after cardiac surgery. Kardiochir. Torakochir. Pol. 2017;14(4):230-235. doi: 10.5114/kitp.2017.72226.


35. Alshamsi F, Alshammari K, Belley-Cote E, Dionne J, Albrahim T, Albudoor B, Ismail M, Al-Judaibi B, Baw B, Subramanian RM, Steadman R, Galusca D, Huang DT, Nanchal R, Al Quraini M, Yuan Y, Alhazzani W. Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials. Intensive Care Med. 2020;46(1):1-16. doi: 10.1007/s00134-019-05783-y.


36. Nand N, Verma P, Jain D. Comparative evaluation of continuous veno-venous hemodiafiltration and continuous arterio-venous hemodiafiltration in patients of hepatic failure and / or hepatorenal syndrome. J. Assoc. Physicians India. 2019;67(8):39-42.


37. Warrillow S, Fisher C, Bellomo R. Correction and control of hyperammonemia in acute liver failure: the impact of continuous renal replacement timing, intensity, and duration. Crit. Care Med. 2019. doi: 10.1097/CCM.0000000000004153.


38. Ide K, Muguruma T, Shinohara M, Toida C, Enomoto Y, Matsumoto S, Aoki K, Fukuda A, Sakamoto S, Kasahara M. Continuous veno-venous hemodiafiltration and plasma exchange in infantile acute liver failure. Pediatr. Crit. Care Med. 2015;16(8):e268-274. doi: 10.1097/PCC.0000000000000511.


39. Li GL, Wang SM. The development and status of bioartificial liver. Zhonghua Wai Ke Za Zhi. 2017;55(12):957-959. doi: 10.3760/cma.j.issn.0529-5815.2017.12.018.


40. Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future. Gut. 2009;58(12):1690-1702. doi: 10.1136/gut.2008.175380.


41. Ciężkowska M, Pluta K. Clinical applications of liver support systems. Post. Biochem. 2019;65(3):193-201. doi: 10.18388/pb.2019_269.


42. Duan Z, Xin S, Zhang J, You S, Chen Y, Liu H, Zheng S, Li Z, Ashley R, Millis M. Comparison of extracorporeal cellular therapy (ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute on chronic liver failure. Hepat. Med.: Evid. Res. 2018;10:139-152. doi: 10.2147/HMER.S180246.


43. Thompson J, Jones N, Al-Khafaji A, Malik S, Reich D, Munoz S, MacNicholas R, Hassanein T, Teperman L, Stein L, Duarte-Rojo A, Malik R, Adhami T, Asrani S, Shah N, Gaglio P, Duddempudi A, Borg B, Jalan R, Brown R, Patton H, Satoskar R, Rossi S, Parikh A, ElSharkawy A, alcoholic hepatitis: a multinational, prospective, controlled, randomized trial. Liver Transpl. 2018;24(3):380-393. doi: 10.1002/lt.24986.


44. Ren S, Irudayam JI, Contreras D, Sareen D, Talavera-Adame D, Svendsen CN, Arumugaswami V. Bioartificial liver device based on induced pluripotent stem cell-derived hepatocytes. J. Stem Cell Res. Ther. 2015;5(2):5-9. doi: 10.4172/2157-7633.1000263.


45. Van Wenum M, Adam AA, Hakvoort TB, Hendriks EJ, Shevchenko V, van Gulik TM, Chamuleau RA, Hoekstra R. Selecting cells for bioartificial liver devices and the importance of a 3D culture environment: a functional comparison between the HepaRG and C3A cell lines. Int. J. Biol. Sci. 2016;12(8):964-978. doi: 10.7150/ijbs.15165.


46. Nicolas CT, Hickey RD, Chen HS, Mao SA, Lopera Higuita M, Wang Y, Nyberg SL. Concise review: liver regenerative medicine: from hepatocyte transplantation to bioartificial livers and bioengineered grafts. Stem Cells. 2017;35(1):42-50. doi: 10.1002/stem.2500.


Просмотров аннотации: 91
Загрузок PDF: 47
Опубликован
2020-06-02